MADISON, Wis. – Voximetry, a pioneer in advanced technology to enable personalized treatments for late-stage cancer patients, announced the addition of Dr. Michael Stabin as a key advisor, a move that underscores its commitment to advancing radiopharmaceutical dosimetry solutions. With an extensive background in health physics and nuclear engineering, Dr. Stabin brings over four decades of experience in education, research, and practical application in the field.
As a world-renowned leader of radiation dose calculations in nuclear medicine, Dr. Stabin has received numerous accolades, including the Elda E. Anderson Award and the Hal Anger Lectureship. He has served as President of the Medical Section of the Health Physics Society and as an Associate Editor for the Journal of Nuclear Medicine and Health Physics Journal.
“We are humbled and honored to have the inventor of OLINDA endorse where we are headed with advanced RPT dosimetry,” said Dr. Sue Wallace, CEO of Voximetry. “His deep insight into radiation transport, tumor and organ dosimetry, and translational considerations from pre-clinical to humans are unmatched and will help us accelerate our Torch software and Pharma services to meet the demands of current and future radiopharmaceutical users and developers.”
Dr. Stabin is best known for developing the MIRDOSE software and then OLINDA/EXM, a tool that automates internal dose estimates in nuclear medicine and is utilized in over 2,000 sites globally.
Most recently, Dr. Stabin served as a Physicist and Instructor at NV5/Dade Moeller, where he played a pivotal role in supporting radiation workers at the Hanford site. His work included conducting in-vivo and in-vitro bioassay analyses, contributing to national and international conferences, and consulting for the International Atomic Energy Agency. Dr. Stabin’s ability to communicate complex concepts through short courses and seminars has made him a sought-after educator, with invitations to over 30 countries.
Prior to his tenure at NV5, Dr. Stabin was an Associate Professor at Vanderbilt University, where he authored the OLINDA/EXM software, taught graduate courses in radiological protection, and chaired the Radiation Safety Committee. His experience extends to consulting roles and teaching positions at various institutions, including Oak Ridge Associated Universities and the Illinois Institute of Technology.
ABOUT VOXIMETRY
Voximetry is committed to enabling personalized and effective theranostic treatment options for patients worldwide through wide-ranging collaboration, deep scientific expertise, and technology-forward progress. Based in Madison, Wisconsin, Voximetry is a Healthtech software and services company pioneering patient-specific radiopharmaceutical treatment planning (RPT) in advanced stage cancer patients.
ABOUT TORCH
Torch® Dose Assessment software is a proprietary product developed by Voximetry and approved for clinical use by the FDA. Torch design and development continues to be supported by the National Cancer Institute of the National Institutes of Health under Award Numbers R43CA221491 and 2R44CA291564. The product is solely the responsibility of Voximetry and does not represent the official views of the National Institutes of Health.